Durvalumab after Chemoradiotherapy in Stage III Non-small-cell Lung Cancer

Abstract

Hepatocellular carcinoma (HCC) is a major global health problem and the most frequent primary liver tumor. Although there are widespread applications of cancer-screening systems to detect early-stage HCC, a significant proportion of patients are still diagnosed with non-resectable HCC. In Thailand, according to the Thai Association for the Study of the Liver, which is an improved version of Barcelona Clinic Liver Cancer (BCLC) staging, the advanced stage characterizes patients with cancer-related symptoms, macrovascular invasion (either segmental or main portal vein) or extrahepatic spread (lymph node involvement),or metastases. Untreated advanced-stage HCC had a poor prognosis, with a survival time of 6-8 months; survival at 1 year was 25%. There are currently many treatments for  advanced HCC, one of which is systemic therapy. Sorafenib was the first molecular target agent with supportive evidence of survival benefits; it has now become the first-line treatment for patients with advanced HCC. In the past few years, more agents have been approved by the USFDA for patients with advanced HCC. This article reviews the role of the currently approved systemic therapy for advanced HCC according to the National Comprehensive Cancer Network (NCCN) guidelines.